Kither Biotech completes Phase 1 of inhaled peptide KIT2014 in COPD
Kither Biotech has completed a first-in-human Phase 1 study of KIT2014, its inhaled peptide candidate targeting multiple respiratory disease pathways, reporting a clean safety and tolerability readout across all dose levels tested. The company said the results support progression into patient studies, with COPD the stated priority for the next clinical stage.
The double-blind, randomised, placebo-controlled trial enrolled 56 healthy participants and ran in two parts: a single ascending dose cohort and a multiple ascending dose cohort. KIT2014 was administered at daily doses ranging from 0.1 mg to 2 mg for up to seven days. A key secondary finding was that blood plasma concentrations remained below the limit of detection at all dose levels, indicating that inhaled delivery confines the drug to the lung and produces very low systemic exposure.
The science behind KIT2014
KIT2014 is a 42-amino-acid cell-permeable peptide that inhibits phosphodiesterase 3 and 4 (PDE3/4) in balanced measure, raising local concentrations of cyclic AMP (cAMP) in airway cells. The company says this dual mechanism simultaneously promotes bronchodilation through relaxation of airway smooth muscle, reduces neutrophil-driven inflammation, and enhances CFTR gating to improve chloride ion transport and mucus clearance. The third effect is particularly relevant for cystic fibrosis patients, where residual mucus burden persists even in those receiving CFTR modulator therapy.
Dimitrios Goundis, chief executive, said the results "demonstrate KIT2014's favourable safety and tolerability profile" and that the dual PDE3/4 inhibition "offers the potential for multiple therapeutic benefits." Anita van der Meer, director of Kither Biotech Pty Ltd, added that the absence of measurable systemic exposure at all dose levels "provides a strong foundation for advancing into patient studies."
Market context and competitive landscape
Respiratory disease represents a large and commercially active therapeutic area, but the inhaled PDE inhibitor class carries a complicated history. Roflumilast, an oral selective PDE4 inhibitor marketed by AstraZeneca and generics manufacturers, is an established COPD add-on therapy; however, class-wide tolerability concerns driven by systemic gastrointestinal side effects have historically limited uptake. An inhaled approach that avoids systemic exposure could sidestep those issues, which is the clinical hypothesis Kither now has an opportunity to test in patients.
Non-CF bronchiectasis is a comparatively underserved indication. Insmed's brensocatib, an oral dipeptidyl peptidase-1 inhibitor, received FDA approval for NCFB in 2025 and represents the first approved therapy in the indication, raising the bar for subsequent entrants but also validating the commercial opportunity. CFTR modulators from Vertex Pharmaceuticals have transformed outcomes for eligible CF patients, but a meaningful proportion of the patient population cannot access or respond fully to modulator therapy, leaving room for complementary inhaled approaches.
Kither has raised $26 million to date from a syndicate that includes Claris Ventures, CDP Venture Capital and a number of Italian angel and family-office investors. The company's leadership is attending the BIO International Convention in San Diego later this month, signalling an active business development posture as it prepares Phase 2 designs. Key near-term milestones for investors will be the selection of a lead Phase 2 indication, the choice of trial endpoints in a patient population, and any partnership or out-licensing discussions that may be disclosed at BIO.